Aberdeen Group plc Invests $4.42 Million in Arcus Biosciences, Inc. $RCUS

Aberdeen Group plc bought a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 331,671 shares of the company’s stock, valued at approximately $4,418,000.

A number of other institutional investors also recently modified their holdings of RCUS. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares during the period. Abich Financial Wealth Management LLC acquired a new position in Arcus Biosciences during the third quarter worth $69,000. CWM LLC increased its holdings in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after buying an additional 3,810 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after buying an additional 1,796 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $16.00 to $28.00 in a report on Monday, January 12th. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. Truist Financial set a $30.00 price objective on shares of Arcus Biosciences in a research report on Friday, December 12th. Finally, UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.33.

Insider Activity

In other news, COO Jennifer Jarrett sold 11,225 shares of Arcus Biosciences stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $245,603.00. Following the sale, the chief operating officer directly owned 203,007 shares in the company, valued at $4,441,793.16. The trade was a 5.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Terry J. Rosen sold 28,947 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the transaction, the chief executive officer owned 2,220,553 shares in the company, valued at approximately $48,585,699.64. The trade was a 1.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 265,887 shares of company stock valued at $6,075,020 over the last quarter. 9.60% of the stock is owned by insiders.

Arcus Biosciences Price Performance

Shares of RCUS opened at $18.98 on Friday. The stock has a market cap of $2.05 billion, a P/E ratio of -5.52 and a beta of 0.84. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $26.40. The business’s fifty day moving average is $21.79 and its 200 day moving average is $18.08.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.